These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12502676)

  • 1. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.
    Raji A; Seely EW; Bekins SA; Williams GH; Simonson DC
    Diabetes Care; 2003 Jan; 26(1):172-8. PubMed ID: 12502676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Pagkalos EM; Hitoglou-Makedou AD; Pliakos CI; Kazakos KA; Yovos JG; Zebekakis PE; Tziolas IM; Tourkantonis AN
    J Hypertens; 2004 Sep; 22(9):1769-77. PubMed ID: 15311106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance.
    Bennett SM; Agrawal A; Elasha H; Heise M; Jones NP; Walker M; Wilding JP
    Diabet Med; 2004 May; 21(5):415-22. PubMed ID: 15089784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].
    Li GW; Wang JP; Li CM; Chen YY; Yang WY; Xing XY; Liu KL; Tang YL; Li H
    Zhonghua Nei Ke Za Zhi; 2004 Dec; 43(12):907-10. PubMed ID: 15730735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
    Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
    Yosefy C; Magen E; Kiselevich A; Priluk R; London D; Volchek L; Viskoper RJ
    J Cardiovasc Pharmacol; 2004 Aug; 44(2):215-22. PubMed ID: 15243303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.
    Schneider F; Vossler S; Franke S; Bär F; Konrad T
    Int J Clin Pharmacol Ther; 2009 May; 47(5):311-20. PubMed ID: 19473593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance.
    Dorella M; Giusto M; Da Tos V; Campagnolo M; Palatini P; Rossi G; Ceolotto G; Felice M; Semplicini A; Del Prato S
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1568-74. PubMed ID: 8636369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating ApoJ is closely associated with insulin resistance in human subjects.
    Seo JA; Kang MC; Ciaraldi TP; Kim SS; Park KS; Choe C; Hwang WM; Lim DM; Farr O; Mantzoros C; Henry RR; Kim YB
    Metabolism; 2018 Jan; 78():155-166. PubMed ID: 28986164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
    Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.
    Gelato MC; Mynarcik DC; Quick JL; Steigbigel RT; Fuhrer J; Brathwaite CE; Brebbia JS; Wax MR; McNurlan MA
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):163-70. PubMed ID: 12394794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
    Beeson M; Sajan MP; Dizon M; Grebenev D; Gomez-Daspet J; Miura A; Kanoh Y; Powe J; Bandyopadhyay G; Standaert ML; Farese RV
    Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.
    Walker AB; Chattington PD; Buckingham RE; Williams G
    Diabetes; 1999 Jul; 48(7):1448-53. PubMed ID: 10389852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.
    Rennings AJ; Smits P; Stewart MW; Tack CJ
    Diabetes Care; 2006 Mar; 29(3):581-7. PubMed ID: 16505510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
    Stühlinger MC; Abbasi F; Chu JW; Lamendola C; McLaughlin TL; Cooke JP; Reaven GM; Tsao PS
    JAMA; 2002 Mar; 287(11):1420-6. PubMed ID: 11903029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.